On Monday, May 7, during a poster session at the 2018 Annual Meeting of the American Psychiatric Association, researchers presented new data on the injectable antipsychotic treatment aripiprazole lauroxil (Aristada), which is indicated for the treatment of schizophrenia.
This page contains sponsored advertising.
On Monday, May 7, during a poster session at the 2018 Annual Meeting of the American Psychiatric Association, held in New York, New York, researchers presented new data on the injectable antipsychotic treatment aripiprazole lauroxil (AL; Aristada), which is indicated for the treatment of schizophrenia.
David Walling, PhD, presented findings1 from a phase 1 pharmacokinetic, safety, and tolerability study of a potential 1-day initiation regimen for AL. Currently, AL injection requires 21 days of orally administered aripiprazole supplementation to achieve therapeutic levels. For patients who initiate their treatment with AL in a hospital setting, a 1-day initiation regimen would provide an alternative to oral supplementation that could assure therapeutic levels of the drug at the time that they are discharged form inpatient treatment.
The proposed 1-day regimen uses a nano-crystalline milled dispersion of AL; the small particle size allows the drug to dissolve more quickly, and is intended to result in therapeutic levels when it is given together with the first oral dose of AL.
The blinded, randomized, phase 1 study compared the 1-day initiation regimen (injection of the nano-crystalline milled dispersion plus a 30 mg dose of oral aripiprazole) with the standard approach (injection of AL at a dose of either 441 or 882 mg plus 21 daily 15 mg doses of oral aripiprazole). Patients—of whom 161 were enrolled and 133 completed the study—were randomized to either the 1-day initiation regimen or the standard regimen.
The researchers found that the 1-day initiation group had comparable aripiprazole concentrations to the 21-day initiation group. Reported adverse events were injection-site pain, headache, increased weight, insomnia, dyspepsia, and anxiety. A total of 9 akathisia events occurred (4 events in 4 patients in the 1-day group and 5 events in 2 patients in the 21-day group). Eight of these events were mild, and none led to discontinuation of treatment.
Walling and his team concluded that the combination of the of the nano-crystalline milled dispersion with 30 mg of oral aripiprazole was well tolerated, and an adequate alternative to a standard initiation regimen. The 1-day regimen, said the researchers, is currently under review by the FDA.
Also presenting research2 on AL was Leslie L Citrome, MD, MPH. Citrome and his team sought to translate data from clinical trials into Number Needed to Treat (NNT) metrics for the benefits of medications (the number of patients who would need to be treated with a therapy in order to prevent 1 negative outcome) and Number Needed to Harm (NNH) metrics (the number of patients who would need to be exposed to a therapy in order to cause harm in 1 patient), an approach that they say can provide clinicians with guidance for using AL to treat patients with schizophrenia.
The researchers drew efficacy and tolerability data from the pivotal, double-blind, placebo-controlled study of AL in patients with acute episodes of schizophrenia, and calculated NNT and NNH values using those data.
They found that, pooling the 2 doses of AL (441 mg and 882 mg every 4 weeks), the percentage of patients who improved by 30% or more on the Positive and Negative Syndrome Scale (PANSS) were 35.3% for patients receiving AL and 18.4% for those receiving placebo, yielding a NNT of 6 (95% CI, 5-12). At a lower threshold for response (a 20% improvement in PANSS), the NNT was 4.
Akathisia was the only AE that both had an incidence of 5% or greater in patients receiving AL and was twice the rate of the group receiving the placebo, yielding a NNH of 14 (95% CI, 9-33). AL, say the researchers, was 2.3 times more likely to produce a therapeutic response than an incident of akathisia.
“Using the metrics of NNT and NNH, efficacy and safety results were consistent with prior aripiprazole clinical trials for the treatment of patients with an acute exacerbation of schizophrenia,” concluded the authors.
References
1. Walling D, Hard M, Wehr A, Du Y, Weiden PJ, von Moltke L. Aripiprazole lauroxil NanoCrystal dipsersion: a potential 1-day initiation regimen for long-acting aripiprazole lauroxil. Presented at the American Psychiatric Association 2018 meeting, May 7, 2018; New York, New York. Abstract 142.
2. Citrome LL, Du Y, Weiden PJ. Translating trial endpoint to NTT, NNH, and LHH: a re-analysis of the pivotal trial of aripiprazole lauroxil for the treatment of schizophrenia. Presented at the American Psychiatric Association 2018 meeting, May 7, 2018; New York, New York. Abstract 159.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More